# Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)

> **NCT06992739** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Xiamen University** · enrollment: 49 (estimated)

## Conditions studied

- NSCLC (Advanced Non-small Cell Lung Cancer)
- EGFR
- Myelosuppression

## Interventions

- **DRUG:** Trilaciclib and Sacituzumab Tirumotecan

## Key facts

- **NCT ID:** NCT06992739
- **Lead sponsor:** The First Affiliated Hospital of Xiamen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-08
- **Primary completion:** 2027-03
- **Final completion:** 2027-12
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06992739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06992739, "Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT06992739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*